Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Antimicrob Agents ; 17(2): 147-50, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11165120

RESUMEN

Of the 16,024 patients hospitalized from January 1995 to October 1997, 397 (2.4%) acquired nosocomial pneumonia and the aetiological agent was defined in 101 (25%). About 82% developed late onset pneumonia (>7 days of hospitalization). The site of isolation of microorganisms was bronchoalveolar lavage (BAL) (49%), blood culture (39%), pleural effusion (10%) and (2%) pulmonary tissue. Gram-negative bacteria were responsible for 54% of infections. Staphylococcus aureus (34%) was the most frequent microorganism isolated followed by Acinetobacter baumannii (29%) and Pseudomonas aeruginosa and Klebsiella pneumoniae, responsible for 7% of nosocomial pneumonia. Monotherapy gave good cover for early onset pneumonia, but not for late onset pneumonia. Based on our selection criteria, ciprofloxacin was the best monotherapy for early (50%) and late (31%) onset pneumonia. Vancomycin plus ciprofloxacin gave cover of 85% of early and 64% of late onset pneumonia. Monotherapy with ciprofloxacin and also combination therapy of ciprofloxacin plus vancomycin may be good options as initial empirical therapy for nosocomial pneumonia.


Asunto(s)
Antibacterianos/uso terapéutico , Bacterias/aislamiento & purificación , Infección Hospitalaria/microbiología , Quimioterapia Combinada/uso terapéutico , Neumonía Bacteriana/microbiología , Bacterias/efectos de los fármacos , Sangre/microbiología , Líquido del Lavado Bronquioalveolar/microbiología , Ciprofloxacina/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Humanos , Pulmón/microbiología , Derrame Pleural/microbiología , Neumonía Bacteriana/tratamiento farmacológico , Vancomicina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA